Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 4/20 | 0.39 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13266882 | 0.82 | CTSS (0.38) | AAK1IDO1CTSKCTSS | |
| SCHEMBL5689127 | 0.82 | CTSK (0.42) | CTSLIDO1CTSKCTSSSLC6A4 | |
| SCHEMBL4715530 | 0.81 | SMYD3 (0.46) | CTSKCTSSSLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4715527 | 0.81 | SMYD3 (0.46) | CTSKCTSSSLC6A4SLC6A3SLC6A2 | |
| SCHEMBL3289149 | 0.79 | ATM (0.50) | CTSLCTSKATMCTSS | |
| SCHEMBL27533342 | 0.79 | ATM (0.50) | CTSLCTSKATMCTSS | |
| SCHEMBL5780237 | 0.79 | ATM (0.50) | CTSLCTSKATMCTSS | |
| SCHEMBL5462252 | 0.78 | CTSK (0.41) | CTSKCTSSSSTR1SSTR4SLC6A4 | |
| Bromide SCHEMBL8516032 | 0.78 | CTSS (0.43) | PPARGPPARAPPARDCTSLCTSK | |
| Methylamine SCHEMBL5634041 | 0.77 | ATM (0.48) | CTSLCTSKATMCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714019-B2 | Indole, azaindole and related heterocyclic pyrrolidine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090186933-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2009-07-23 | — | — | US | disclosed |
| US-7531552-B2 | Indole, azaindole and related heterocyclic pyrrolidine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1474135-B9 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080096912-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-24 | — | — | US | disclosed |
| EP-1474135-B1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060287531-A1 | Indole, azaindole and related heterocyclic pyrrolidine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2006-12-21 | — | — | US | disclosed |
| EP-1474135-A4 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1474135-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20030236277-A1 | Indole, azaindole and related heterocyclic pyrrolidine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-12-25 | — | — | US | disclosed |
| WO-2003068221-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096912-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | IDO1, IDO2, INMT | AAK1 2136/4885PPARG 3013/4885PPARA 2846/4885 |
| US-20090186933-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | IDO1, IDO2, INMT | AAK1 2136/4885PPARG 3013/4885PPARA 2846/4885 |
| US-20060287531-A1 | Indole, azaindole and related heterocyclic pyrrolidine derivatives | IDO1, IDO2, INMT | AAK1 2136/4885PPARG 3013/4885PPARA 2846/4885 |
| US-20030236277-A1 | Indole, azaindole and related heterocyclic pyrrolidine derivatives | IDO1, IDO2, INMT | AAK1 2136/4885PPARG 3013/4885PPARA 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.